Ireland – 8 December 2008. Cellix Ltd., an international provider of cell-based screening tools for drug discovery, today announces the relaunch of www.cellixltd.com, which has a fresh new look and theme to coincide with Cellix’s expanding areas of focus.
The decision was taken to improve the functionality of the site to allow existing and potential clients understand more about Cellix’s market leading technology, the VenaFluxTM Platform.
Commenting on the new site, Vivienne Williams, CEO describes the enhancements as 'much more than a redesign. It required a major rethink of how Cellix could better support its clients.’
The new site incorporates a number of significant improvements to support its users, such as clearer navigation based on user needs, online demonstration video of how the VenaFluxTM Platform operates which is essential to gain an understanding of how assays are run and a new and improved Frequently Asked Questions section.
The website includes a number of new features including a Learning Centre, information on therapeutic areas, photographs, details on the VenaFluxTM Platform, and video material on Cellix’s continued development in the scientific arena.
'The Cellix website is easy to navigate and informative - the video demonstration really helps to show how their unique cell-based assay products can be applied to an individual’s research, narrowing the gap between in vitro and in vivo results'. saidDr. Sarah Hudsonfrom Langerlab, MIT, Boston, MA, Magner group, MSSI, UL, Limerick, Ireland. Visit the new website at www.cellixltd.com
About Cellix Ltd
Cellix Ltd. is a privately held instrumentation and cell-based assay company developing technologies that accurately mimic in vivo human blood vessels under physiological flow for cell-based screening in drug discovery. The Company is headquartered in Dublin, Ireland, and maintains offices in New York City. For further information visit www.cellixltd.com.
About VenaFluxEC Platform
The VenaFluxTM Platform, the first semi-automated, high throughput microfluidic cell-based assay system, measures cell adhesion to antibody-coated or endothelial-cell cultured microchannels, producing IC50 curves under shear stress conditions mimicking physiological flow. Using the VenaFluxTM Platform, scientists can rapidly obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states. Relatively rapid analyses reduces drug development costs by accelerating false lead elimination and increasing productivity in pharmaceutical and biotechnology research and development laboratories.
|
|
